ClinicalTrials.gg
CompletedNCT00266799Updated Jun 8, 2017Results posted

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

A Phase 3 interventional study of Pegylated liposomal doxorubicin (SCH 200746) and Capecitabine in Breast Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
10th of 66
210 · median 57
Started
2006
with 7 others
Phase 3
10 of 67
2 open now
Registered
11th of 67
by date
Lead sponsor
5 of 67
Merck Sharp & Dohme LLC

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 10th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2006, is one of 10 in phase 3, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multinational, randomized, multicenter trial designed to compare pegylated liposomal doxorubicin with capecitabine as first line chemotherapy of metastatic breast cancer. The primary objective of the study is to compare the time to disease progression, although overall response rates, overall survival, quality of life, time to treatment failure, and safety and tolerability will also be assessed.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be female.
  • Patients must have disease of a cytological or histological confirmed breast cancer.
  • Patients must be 18 years or older.
  • Patients should have evaluable disease (at least uni-dimensionally according to the criteria in at least one site that has not been irradiated), however, patients who only have non-measurable/evaluable disease are not excluded. Also patients with only bone metastasis are not excluded.
  • Patients must have an (ECOG) 0-2.
  • Patients must have a sufficient to be treated with chemotherapy.
  • Patients must be willing and able to complete study questionnaires.
  • Patients must have adequate renal function as evidenced by serum creatinine \<=1.5 mg/dL, or a of >=45 mL/min (if serum creatinine is > 1.5 mg/dL but \<= 1.8 mg/dL).
  • Patients must have adequate bone marrow function as evidenced by leukocyte count greater than 3.5 g/L, >=9.0 g/dL, and count >=100x10\^9/L.
  • Patients must have adequate liver function as evidenced by of \<=1.5 times the (ULN) and alkaline phosphatase \<=3 times, ULN unless related to liver metastasis.
  • Patients must have Sodium and Potassium values within normal limits.
  • Patients whose clinical condition (co-morbidity) allows a treatment with monotherapy or who expressed their wish to be treated with monotherapy.
  • Patients must have signed an document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • History of receiving prior chemotherapy in the setting (Note: patients may have had

hormonal therapy or chemotherapy in the setting; patients may have received hormonal therapy in metastatic setting, patients may have received local radiotherapy).

  • Patients with positive estrogen- / progesterone-receptor status, where an endocrine therapy is indicated. However, patients progressing under hormonal therapy are not excluded.
  • Patients with known to doxorubicinhydrochlorid or to any of the OR known hypersensitivity to capecitabine or fluorouracil or to any of the excipients.
  • Patients with known DPD (dihydro pyrimidine dehydrogenase) deficiency.
  • Patients who are receiving a concomitant treatment with sorivudine or its chemically related analogues, such as brivudine.
  • Patients who are taking concomitant medications (except bisphosphonates) for metastatic disease, including hormonal therapy, radiation therapy, trastuzumab, or biologicals are also not permitted.
  • Patients with Human epidermal growth factor receptor 2 (Her-2/neu) overexpressing tumors with the most recent evaluation as the relevant result

    • immunologically Her2neu 3+ positive
    • Her2neu-2+ positive and ´Fluorescent in-situ hybridization (FISH)´ positive
  • History of treatment with capecitabine
  • History of treatment with anthracyclines in the adjuvant setting exceeding cumulative doses of anthracyclines by more than 360 mg/m\^2 doxorubicin (or equivalents, i.e. 600mg/m\^2 epirubicine).
  • Patients with anthracycline resistant disease are not permitted. Anthracycline resistance is defined as development of locally recurrent or metastatic disease while on adjuvant anthracycline therapy, or relapse less than 12 months after completion of anthracycline therapy.
  • Strong remission pressure that requires polychemotherapy with the exception of patients who are not suitable for a treatment with polychemotherapy or not accepting polychemotherapy.
  • Evidence of primary or metastatic involving the central nervous system unless previously treated and asymptomatic for 3 months or greater.
  • Patients with reduced liver functions (evidenced by of above 1.5 times the (ULN); alkaline phosphatase above 3 times ULN (except related to liver metastasis, in which case \<=5 x ULN).
  • Dyspnea on exertion.
  • History of cardiac disease, with Class II or greater, or clinical evidence of congestive heart failure or myocardial infarct within less than six months or an (LVEF) below 50%.
  • Woman with with insufficient [e.g. intra-uterine device (IUD) are regarded as sufficient] during the study period and the six months following the last study drug application. All methods based on hormonal contraception are not permitted.
  • Existing pregnancy or lactation (note on pregnancy test). A negative pregnancy test for women of childbearing potential has to be in place prior randomization (Note: A pregnancy test has to be done for patients who are not . Postmenopausal is defined as those not having a menstrual period for 12 months in a row).
  • Existing doubts on ability and willingness of the subject for cooperation.
  • Participation of the subject at a clinical study within the last 30 days.
  • Participation of the subject in the same clinical study at an earlier date.
  • Concomitant participation in another study than the one described here.
  • Abuse of drugs, alcohol, or pharmaceuticals.
  • Any condition, whether medical or non-medical, that may interfere, in the opinion of the investigator, with aim of this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Pegylated liposomal doxorubicin

    Drug: Pegylated liposomal doxorubicin (SCH 200746)

  • Active comparator
    Capecitabine

    Drug: Capecitabine

Interventions

  • pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity

  • capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)

    TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions.

    Time frame: From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death

Secondary outcomes

  1. Number of Participants With an Overall Response (Complete Response [CR] + Partial Response [PR]) Between PLD and Capecitabine Treatment Groups

    Overall responses by investigator assessment/RECIST criteria of participant responses; CR=disappearance of target/nontarget lesions + PR=30% decrease in longest diameter sum (noting baseline sum) of target lesions. RECIST used changes in the largest diameter of target/non-target lesions. Target lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions. Evaluation of progress was repeated every 3 months (+/-7 days) post first date of lesion measurements, in detection absence until the participant´s death.

    Time frame: From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death

  2. Overall Survival Time in the PLD and Capecitabine Treatment Groups

    Survival time was defined as duration time from onset of treatment with the study drug until death.

    Time frame: From Day 1 (Cycle 1) until Death

  3. Time to Treatment Failure in the PLD and the Capecitabine Treatment Groups

    Time to treatment failure was defined as the duration of time from the date of the first administration of the study drug to the date of discontinuation of the study drug for any reason.

    Time frame: From Day 1 (Cycle 1) until End of Treatment

  4. Quality of Life (QoL) Measured by QoL Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) + Subjective Significance Questionnaire (SSQ))

    QoL questionnaire was an EORTC QLQ-C30 \& SSQ integration. Scores on the SSQ scale ranged from 1 (very much worse) - 7 (very much better). SSQ consisted of 4 items which corresponded to core domains in the 30 Item EORTC QLQ-C30, such as improvement/deterioration in physical functioning, emotional functioning, social functioning, global QoL. Percentages were based on number of participants at each cycle \& rounded to the nearest whole number. Early Withdrawal Questionnaires were obtained in 7-14 days of study drug final dose.

    Time frame: From Screening to Day 1 of every Treatment Cycle up to 12 Cycles

07

Results

Posted Nov 16, 2011

Participant flow

210 participants were enrolled with 105 participants randomized for treatment with PLD and 105 participants randomized for treatment with Capecitabine, of which 7 participants in the PLD group and 3 participants in the Capecitabine group were not treated.

Participant flow — Overall Study
MilestonePegylated Liposomal Doxorubicin (PLD)Capecitabine
Started98102
Completed6268
Not completed3634

Outcome measures

PrimaryTime to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)

TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions.

Time frame:
From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death
Reported as:
Median · Months
Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)
MonthsPegylated Liposomal Doxorubicin (PLD)Capecitabine
By Investigator Assessment (ITT)6.02 (5.10 to 8.19)6.05 (4.27 to 9.07)
By RECIST Criteria (ITT)6.58 (5.29 to 8.19)7.10 (4.77 to 9.53)
By Investigator Assessment (TTP N = 63, N = 59)5.85 (4.37 to 7.86)5.88 (2.99 to 8.98)
By RECIST Criteria (TTP N = 63, N = 59)6.02 (4.37 to 7.86)6.05 (4.08 to 9.27)
Statistical analysis
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.6686 · Hazard ratio (hr): 1.08 · 95% CI 0.76 to 1.54
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.4472 · Hazard ratio (hr): 1.15 · 95% CI 0.80 to 1.65
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.5508 · Hazard ratio (hr): 1.14 · 95% CI 0.74 to 1.77
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.4088 · Hazard ratio (hr): 1.21 · 95% CI 0.77 to 1.89
SecondaryNumber of Participants With an Overall Response (Complete Response [CR] + Partial Response [PR]) Between PLD and Capecitabine Treatment Groups

Overall responses by investigator assessment/RECIST criteria of participant responses; CR=disappearance of target/nontarget lesions + PR=30% decrease in longest diameter sum (noting baseline sum) of target lesions. RECIST used changes in the largest diameter of target/non-target lesions. Target lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions. Evaluation of progress was repeated every 3 months (+/-7 days) post first date of lesion measurements, in detection absence until the participant´s death.

Time frame:
From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death
Reported as:
Number · Participants
Number of Participants With an Overall Response (Complete Response [CR] + Partial Response [PR]) Between PLD and Capecitabine Treatment Groups
ParticipantsPegylated Liposomal Doxorubicin (PLD)Capecitabine
By Investigator Assessment - CR10
By Investigator Assessment - PR512
By Investigator Assessment Overall Response612
By RECIST Criteria - CR10
By RECIST Criteria - PR811
By RECIST Criteria Overall Response911
Statistical analysis
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Chi-squared · p = 0.1726
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Chi-squared · p = 0.6541
SecondaryOverall Survival Time in the PLD and Capecitabine Treatment Groups

Survival time was defined as duration time from onset of treatment with the study drug until death.

Time frame:
From Day 1 (Cycle 1) until Death
Reported as:
Median · Months
Overall Survival Time in the PLD and Capecitabine Treatment Groups
MonthsPegylated Liposomal Doxorubicin (PLD)Capecitabine
Overall Survival Time in the PLD and Capecitabine Treatment Groups23.31 (21.44 to 27.52)26.79 (18.67 to 32.28)
Statistical analysis
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.5265 · Hazard ratio (hr): 1.12 · 95% CI 0.79 to 1.58
SecondaryTime to Treatment Failure in the PLD and the Capecitabine Treatment Groups

Time to treatment failure was defined as the duration of time from the date of the first administration of the study drug to the date of discontinuation of the study drug for any reason.

Time frame:
From Day 1 (Cycle 1) until End of Treatment
Reported as:
Median · Months
Time to Treatment Failure in the PLD and the Capecitabine Treatment Groups
MonthsPegylated Liposomal Doxorubicin (PLD)Capecitabine
Time to Treatment Failure in the PLD and the Capecitabine Treatment Groups4.60 (3.35 to 4.93)3.68 (2.93 to 5.85)
Statistical analysis
  • Pegylated Liposomal Doxorubicin (PLD) vs Capecitabine · Log Rank · p = 0.0841 · Hazard ratio (hr): 1.29p-value also given for Hazard Ratio
SecondaryQuality of Life (QoL) Measured by QoL Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) + Subjective Significance Questionnaire (SSQ))

QoL questionnaire was an EORTC QLQ-C30 \& SSQ integration. Scores on the SSQ scale ranged from 1 (very much worse) - 7 (very much better). SSQ consisted of 4 items which corresponded to core domains in the 30 Item EORTC QLQ-C30, such as improvement/deterioration in physical functioning, emotional functioning, social functioning, global QoL. Percentages were based on number of participants at each cycle \& rounded to the nearest whole number. Early Withdrawal Questionnaires were obtained in 7-14 days of study drug final dose.

Time frame:
From Screening to Day 1 of every Treatment Cycle up to 12 Cycles
Reported as:
Number · Percentage of Participants
Quality of Life (QoL) Measured by QoL Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) + Subjective Significance Questionnaire (SSQ))
Percentage of ParticipantsPegylated Liposomal Doxorubicin (PLD)Capecitabine
Screening - Very Much Worse414
Screening - Moderately Worse814
Screening - A Little Worse1224
Screening - About the Same6741
Screening - A Little Better40
Screening - Moderately Better20
Screening - Very Much Better27
Cycle 1 - Very Much Worse09
Cycle 1 - Moderately Worse109
Cycle 1 - A Little Worse229
Cycle 1 - About the Same6365
Cycle 1 - A Little Better52
Cycle 1 - Moderately Better05
Cycle 1 - Very Much Better00
Cycle 2 - Very Much Worse311
Cycle 2 - Moderately Worse98
Cycle 2 - A Little Worse2515
Cycle 2 - About the Same5150
Cycle 2 - A Little Better99
Cycle 2 - Moderately Better15
Cycle 2 - Very Much Better13
Cycle 3 - Very Much Worse43
Cycle 3 - Moderately Worse1313
Cycle 3 - A Little Worse1323
Cycle 3 - About the Same5848
Cycle 3 - A Little Better810
Cycle 3 - Moderately Better42
Cycle 3 - Very Much Better00
Cycle 4 - Very Much Worse46
Cycle 4 - Moderately Worse1112
Cycle 4 - A Little Worse2622
Cycle 4 - About the Same4755
Cycle 4 - A Little Better92
Cycle 4 - Moderately Better24
Cycle 4 - Very Much Better00
Cycle 5 - Very Much Worse50
Cycle 5 - Moderately Worse02
Cycle 5 - A Little Worse2119
Cycle 5 - About the Same4062
Cycle 5 - A Little Better1914
Cycle 5 - Moderately Better102
Cycle 5 - Very Much Better50
Cycle 6 - Very Much Worse53
Cycle 6 - Moderately Worse76
Cycle 6 - A Little Worse911
Cycle 6 - About the Same5860
Cycle 6 - A Little Better1414
Cycle 6 - Moderately Better53
Cycle 6 - Very Much Better23
Cycle 7 - Very Much Worse03
Cycle 7 - Moderately Worse43
Cycle 7 - A Little Worse1723
Cycle 7 - About the Same5242
Cycle 7 - A Little Better136
Cycle 7 - Moderately Better1316
Cycle 7 - Very Much Better06
Cycle 8 - Very Much Worse03
Cycle 8 - Moderately Worse136
Cycle 8 - A Little Worse1716
Cycle 8 - About the Same5761
Cycle 8 - A Little Better96
Cycle 8 - Moderately Better06
Cycle 8 - Very Much Better40
Cycle 9 - Very Much Worse60
Cycle 9 - Moderately Worse03
Cycle 9 - A Little Worse2521
Cycle 9 - About the Same5055
Cycle 9 - A Little Better610
Cycle 9 - Moderately Better63
Cycle 9 - Very Much Better67
Cycle 10 - Very Much Worse04
Cycle 10 - Moderately Worse88
Cycle 10 - A Little Worse1713
Cycle 10 - About the Same6750
Cycle 10 - A Little Better813
Cycle 10 - Moderately Better04
Cycle 10 - Very Much Better08
Cycle 11 - Very Much Worse00
Cycle 11 - Moderately Worse119
Cycle 11 - A Little Worse013
Cycle 11 - About the Same6739
Cycle 11 - A Little Better1113
Cycle 11 - Moderately Better119
Cycle 11 - Very Much Better017
Cycle 12 - Very Much Worse04
Cycle 12 - Moderately Worse08
Cycle 12 - A Little Worse1113
Cycle 12 - About the Same7850
Cycle 12 - A Little Better1113
Cycle 12 - Moderately Better08
Cycle 12 - Very Much Better04

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Liposomal Doxorubicin (PLD)—30/98 (30.6%)96/98 (98%)
Capecitabine—46/102 (45.1%)98/102 (96.1%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventPegylated Liposomal Doxorubicin (PLD)Capecitabine
DIARRHOEAGastrointestinal disorders2/988/102
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/986/102
DYSPNOEARespiratory, thoracic and mediastinal disorders2/985/102
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders4/982/102
HAEMOGLOBIN DECREASEDInvestigations1/984/102
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders1/984/102
DISEASE PROGRESSIONGeneral disorders0/983/102
FATIGUEGeneral disorders2/983/102
PYREXIAGeneral disorders0/983/102
MALIGNANT PLEURAL EFFUSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/983/102
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPegylated Liposomal Doxorubicin (PLD)Capecitabine
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders65/9868/102
FATIGUEGeneral disorders53/9854/102
EAR, NOSE AND THROAT EXAMINATION ABNORMALInvestigations42/9817/102
NAUSEAGastrointestinal disorders41/9841/102
DIARRHOEAGastrointestinal disorders14/9842/102
STOMATITISGastrointestinal disorders39/9817/102
WHITE BLOOD CELL COUNT DECREASEDInvestigations37/9816/102
ALOPECIASkin and subcutaneous tissue disorders27/9810/102
VOMITINGGastrointestinal disorders18/9828/102
CONSTIPATIONGastrointestinal disorders25/9810/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegylated Liposomal Doxorubicin (PLD)CapecitabineTotal
Mean61.4 ± 10.6661.5 ± 10.5961.5 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated Liposomal Doxorubicin (PLD)CapecitabineTotal
Female105105210
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2. PubMed 34037241 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Sep 2010, 56 months.

Results were first posted in Nov 2011, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 56 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2005
First posted
Dec 19, 2005
StartActual
Jan 13, 2006
Primary completionActual
Sep 29, 2010
CompletionActual
Oct 18, 2010
Results first posted
Nov 16, 2011
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00266799
Collaborators
Essex Pharma GmbH
Responsible party
Sponsor
First posted
Dec 19, 2005
Start date
Jan 13, 2006
Primary completion
Sep 29, 2010
Completion
Oct 18, 2010
Results posted
Nov 16, 2011
Last update
Jun 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion